TeamDrive
RUS

Russian State Duma to ease imports of APIs

11 January 2018

Remedium

The Russian national Parliament (State Duma) plans to approve a bill that will ease imports of active pharmaceutical ingredients (APIs) to the country, according to press-service of the Russian Duma, reports The Pharma Letter’s local correspondent.

Under the current Russian legislation, the country’s state register of drugs usually contains information about an active substance of the drug, instead of a finished product. Therefore drug imports to Russia are usually associated with the need to conduct several examinations of these products. The first of them involves checking the quality of the substance in the composition of the drug, while the second one checking an actual presence of an active substance.

A spokesman of the Russian State Duma said the new state initiative could be beneficial for domestic drugmakers, as it will provide significant savings for them, both in terms of finance and timing. According to him, the existence of such checks significantly slows down and increases the cost of import substitution for the Russian pharmaceutical industry. This leads to discrimination against domestic producers, and significantly increases the time and cost of finished products.

At the same time, such requirements do not apply to foreign manufacturers, which are only required to register a finished product in the state register.

In this regard, the State Duma proposes to determine that an active pharmaceutical ingredient is considered included in the state register of drugs since the inclusion of a drug (in which composition it included) into it. Such a rule is proposed to extend to the purchases, imports and any other use of such substances.

Source


Previous publication Next publication

Media Center

  • 22 June 2018

    Drug shortages again on the rise after 5 years of improvements, FDA says

    After 5 years of declines in the number of new drug shortages in the U.S., they jumped to 39 last year from 26 in the two preceding years. And while that is a far cry from the peak of more than 250 registered in 2011, the FDA acknowledges that many of the current shortages have been for critical drug products and “are having a tangible impact on patients.”

  • 22 June 2018

    Pfizer’s 'Living With Cancer' wowed Cannes attendees, if not the pharma jury

    A Pfizer documentary film about five patients living with cancer may have inspired more fanfare at Cannes Lions Health than it did in the eight months since its launch. The “This is Living With Cancer” film and its associated campaign was shortlisted for a pharma award at the annual ad festival and was heaped with praise after Pfizer presented it in an open session.

  • 21 June 2018

    EvaluatePharma World Preview 2018, Outlook to 2024

    EvaluatePharma World Preview 2018, Outlook to 2024

    And according to EvaluatePharma’s World Preview 2018, we are looking at an industry set to experience sales accelerating from the sluggish levels following the financial crisis, to annual compound growth of over 6% between now and 2024. 

  • 21 June 2018

    Russian equipment for storage of thermolabile drugs was delivered to China

    POZIS JSC, an affiliate of Techmash concern of Rostec Corporation, for the first time delivered Russian medical equipment to Hong Kong. Under the contract, the customer received HF-140 POZIS, pharmaceutical refrigerators designed for storage of thermolabile drugs, and RBC-2, new generation compact bactericidal recirculators for air disinfection.

Read more